Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The "PRONE" Study
The overall objective of this study is to determine whether a positional maneuver (e.g., prone positioning) decreases the need for escalation of respiratory-related care in patients with coronavirus (COVID-19) pneumonia.
As the initial outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the disease it causes, coronavirus disease 2019 (COVID-19) has spread beyond Wuhan, China it has become a pandemic affecting over 178 countries. Of patients admitted to the ICU, upwards of 85% developed the acute respiratory distress syndrome (ARDS) and most if not all required mechanical ventilation. The beneficial effects of prone positioning for ARDS have been well described. Coupling the reported benefits of prone positioning in COVID-19 associated ARDS patients with the known beneficial effects of early prone-positioning in the treatment of ARDS, it is not surprising that many hospital systems are advocating prone positioning for treatment of ARDS in patients with COVID-19. However, as the pandemic continues to progress in the United States and the number of new cases grows as new clusters emerge, the possibility of 'rationing' ventilators becomes more real. Therefore, therapies that prevent the need for mechanical ventilation are desperately needed. Given the distinct benefit that patients with COVID-19 have with prone positioning, the overarching hypothesis of this trial is that patients with high risk for respiratory failure may also benefit from prone positioning.
Arms and Interventions
|No Intervention: Control - Usual Care|
|Experimental: Intervention - Prone Positioning|
Other: Prone Positioning
Primary Outcome Measures
- Occurrence of an escalation in respiratory related care (yes vs no) [During hospitalization, up to 30 days]
Participants will be assessed for the occurrence of an escalation in respiratory related care (Yes or No). Escalation in respiratory related care is clinically defined as any of the following: intubation any increase in flow of supplemental oxygen transition to high flow nasal cannula increase in fraction of inspired oxygen transfer from a lower to a higher level acuity of care (e.g. medical floor to intermediate care unit (IMC) or intensive care unit (ICU); IMC to ICU).
Secondary Outcome Measures
- Oxygen Saturation [Over a consecutive 24-hour period after randomization]
Oxygen Saturation measured in percent oxygen over a 24-hour period.
- Respiratory Effort as assessed by Respiratory Rate [Over a consecutive 24-hour period after randomization]
Respiratory effort will be assessed using the respiratory rate (in breaths per minute) over a 24-hour period.
Age ≥ 18 years
COVID-19 positive by nasopharyngeal swab or serostatus
Use of supplemental oxygen OR respiratory rate ≥ 20
BMI ≥ 45 kg/m2
Chest tube placement
Hemodynamic instability with mean arterial pressure < 60 mmHg
Thoracic or abdominal wounds
Chest wall deformities
Vertebral column deformities that would preclude prone positioning
Facial trauma or surgery in the last 30 days
Established diagnosis of interstitial lung disease
Prior single or double lung transplant
Surgery for spine, femur, or pelvis in the last 3 months
Thoracic or cardiac surgery in the last 30 days
Pacemaker placement last 7 days
Contacts and Locations
|1||Johns Hopkins Univeristy||Baltimore||Maryland||United States||21287|
|2||University of North Carolina||Chapel Hill||North Carolina||United States||27514|
|3||Duke University||Durham||North Carolina||United States||27710|
Sponsors and Collaborators
- Johns Hopkins University
- Duke University
- University of North Carolina
- University of Miami
- University of Pittsburgh
- Smith & Nephew, Inc.
- Nox Medical Iceland
- Principal Investigator: Naresh Punjabi, MD, Johns Hopkins University
Study Documents (Full-Text)None provided.